BioCryst Pharmaceuticals (NASDAQ: BCRX) is one of 287 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare BioCryst Pharmaceuticals to similar companies based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership.
This table compares BioCryst Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BioCryst Pharmaceuticals Competitors||-5,441.68%||-162.70%||-35.92%|
This table compares BioCryst Pharmaceuticals and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BioCryst Pharmaceuticals||$26.35 million||-$55.14 million||-8.77|
|BioCryst Pharmaceuticals Competitors||$290.27 million||$35.99 million||54.45|
BioCryst Pharmaceuticals’ peers have higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent recommendations and price targets for BioCryst Pharmaceuticals and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioCryst Pharmaceuticals Competitors||925||3348||11862||238||2.70|
BioCryst Pharmaceuticals presently has a consensus target price of $9.14, suggesting a potential upside of 62.97%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.55%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe BioCryst Pharmaceuticals is more favorable than its peers.
Risk and Volatility
BioCryst Pharmaceuticals has a beta of 3.05, indicating that its stock price is 205% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals’ peers have a beta of 2.41, indicating that their average stock price is 141% more volatile than the S&P 500.
Institutional & Insider Ownership
84.7% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
BioCryst Pharmaceuticals peers beat BioCryst Pharmaceuticals on 7 of the 13 factors compared.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.